ENSG00000175054 |
ATR |
colorectal adenocarcinoma |
stop_gained |
6.662% (95/1426) |
3 entries |
ENSG00000175054 |
ATR |
hemangioblastoma |
sequence_alteration |
40.0% (14/35) |
1 entry |
ENSG00000175054 |
ATR |
breast ductal adenocarcinoma |
stop_gained |
5.501% (96/1745) |
2 entries |
ENSG00000175054 |
ATR |
Ovarian Endometrioid Adenocarcinoma |
sequence_alteration |
33.33% (6/18) |
1 entry |
ENSG00000175054 |
ATR |
breast ductal adenocarcinoma |
missense_variant |
5.501% (96/1745) |
4 entries |
ENSG00000175054 |
ATR |
breast ductal adenocarcinoma |
conservative_inframe_deletion |
5.501% (96/1745) |
1 entry |
ENSG00000175054 |
ATR |
breast ductal adenocarcinoma |
frameshift_variant |
5.501% (96/1745) |
1 entry |
ENSG00000175054 |
ATR |
colorectal adenocarcinoma |
sequence_alteration |
6.662% (95/1426) |
3 entries |
ENSG00000175054 |
ATR |
colorectal adenocarcinoma |
frameshift_variant |
6.662% (95/1426) |
4 entries |
ENSG00000175054 |
ATR |
Ovarian Endometrioid Adenocarcinoma |
missense_variant |
33.33% (6/18) |
1 entry |
ENSG00000175054 |
ATR |
colorectal adenocarcinoma |
missense_variant |
6.662% (95/1426) |
7 entries |
ENSG00000175054 |
ATR |
breast carcinoma |
missense_variant |
1.579% (26/1647) |
2 entries |
ENSG00000175054 |
ATR |
lung adenocarcinoma |
missense_variant |
2.823% (78/2763) |
6 entries |
ENSG00000175054 |
ATR |
Merkel cell skin cancer |
missense_variant |
3.191% (3/94) |
2 entries |
ENSG00000175054 |
ATR |
urothelial carcinoma |
missense_variant |
8.14% (7/86) |
1 entry |
ENSG00000175054 |
ATR |
small cell lung carcinoma |
missense_variant |
4.289% (19/443) |
4 entries |
ENSG00000175054 |
ATR |
Mixed Lobular and Ductal Breast Carcinoma |
missense_variant |
2.778% (2/72) |
1 entry |
ENSG00000175054 |
ATR |
skin melanoma |
missense_variant |
4.655% (54/1160) |
9 entries |
ENSG00000175054 |
ATR |
esophageal squamous cell carcinoma |
frameshift_variant |
1.608% (11/684) |
2 entries |
ENSG00000175054 |
ATR |
prostate adenocarcinoma |
missense_variant |
3.517% (76/2161) |
2 entries |
ENSG00000175054 |
ATR |
oral squamous cell carcinoma |
stop_gained |
1.901% (5/263) |
2 entries |
ENSG00000175054 |
ATR |
basal cell carcinoma |
missense_variant |
11.76% (8/68) |
1 entry |
ENSG00000175054 |
ATR |
cervical squamous cell carcinoma |
missense_variant |
2.462% (8/325) |
1 entry |
ENSG00000175054 |
ATR |
esophageal adenocarcinoma |
missense_variant |
6.216% (34/547) |
2 entries |
ENSG00000175054 |
ATR |
rectal adenocarcinoma |
missense_variant |
2.364% (13/550) |
3 entries |
ENSG00000175054 |
ATR |
colon adenocarcinoma |
stop_gained |
3.793% (49/1292) |
4 entries |
ENSG00000175054 |
ATR |
breast carcinoma |
stop_gained |
1.579% (26/1647) |
3 entries |
ENSG00000175054 |
ATR |
papillary renal cell carcinoma |
missense_variant |
1.538% (6/390) |
2 entries |
ENSG00000175054 |
ATR |
chronic myelomonocytic leukemia |
missense_variant |
3.158% (3/95) |
1 entry |
ENSG00000175054 |
ATR |
bladder transitional cell carcinoma |
stop_gained |
6.1% (28/459) |
1 entry |
ENSG00000175054 |
ATR |
Uterine Carcinosarcoma |
missense_variant |
6.667% (11/165) |
1 entry |
ENSG00000175054 |
ATR |
colon adenocarcinoma |
sequence_alteration |
3.793% (49/1292) |
3 entries |
ENSG00000175054 |
ATR |
bile duct adenocarcinoma |
missense_variant |
2.08% (13/625) |
2 entries |
ENSG00000175054 |
ATR |
Gallbladder Adenocarcinoma |
missense_variant |
4.124% (8/194) |
2 entries |
ENSG00000175054 |
ATR |
cecum adenocarcinoma |
missense_variant |
4.833% (13/269) |
3 entries |
ENSG00000175054 |
ATR |
female breast carcinoma |
missense_variant |
2.482% (7/282) |
2 entries |
ENSG00000175054 |
ATR |
hemangioblastoma |
missense_variant |
40.0% (14/35) |
1 entry |
ENSG00000175054 |
ATR |
Breast Carcinoma by Gene Expression Profile |
stop_gained |
3.182% (40/1257) |
2 entries |
ENSG00000175054 |
ATR |
pancreatic ductal adenocarcinoma |
missense_variant |
3.446% (58/1683) |
2 entries |
ENSG00000175054 |
ATR |
Mantle cell lymphoma |
missense_variant |
3.448% (2/58) |
2 entries |
ENSG00000175054 |
ATR |
female breast carcinoma |
frameshift_variant |
2.482% (7/282) |
2 entries |
ENSG00000175054 |
ATR |
gastric intestinal type adenocarcinoma |
frameshift_variant |
4.706% (4/85) |
1 entry |
ENSG00000175054 |
ATR |
esophageal adenocarcinoma |
sequence_alteration |
6.216% (34/547) |
1 entry |
ENSG00000175054 |
ATR |
gastric adenocarcinoma |
stop_gained |
3.928% (37/942) |
1 entry |
ENSG00000175054 |
ATR |
endometrium adenocarcinoma |
frameshift_variant |
4.878% (2/41) |
1 entry |
ENSG00000175054 |
ATR |
Endometrial Endometrioid Adenocarcinoma |
missense_variant |
3.105% (39/1256) |
2 entries |
ENSG00000175054 |
ATR |
squamous cell lung carcinoma |
sequence_alteration |
3.94% (37/939) |
1 entry |
ENSG00000175054 |
ATR |
hairy cell leukemia |
missense_variant |
9.524% (2/21) |
1 entry |
ENSG00000175054 |
ATR |
large cell lung carcinoma |
missense_variant |
8.0% (2/25) |
2 entries |
ENSG00000175054 |
ATR |
gastric adenocarcinoma |
sequence_alteration |
3.928% (37/942) |
1 entry |
ENSG00000175054 |
ATR |
ovarian serous adenocarcinoma |
stop_gained |
3.863% (35/906) |
1 entry |
ENSG00000175054 |
ATR |
brain glioblastoma |
missense_variant |
1.714% (21/1225) |
3 entries |
ENSG00000175054 |
ATR |
hepatocellular carcinoma |
sequence_alteration |
2.742% (28/1021) |
1 entry |
ENSG00000175054 |
ATR |
Breast Carcinoma by Gene Expression Profile |
frameshift_variant |
3.182% (40/1257) |
2 entries |
ENSG00000175054 |
ATR |
Gallbladder Adenocarcinoma |
sequence_alteration |
4.124% (8/194) |
1 entry |
ENSG00000175054 |
ATR |
clear cell renal carcinoma |
sequence_alteration |
0.7175% (11/1533) |
1 entry |
ENSG00000175054 |
ATR |
bladder transitional cell carcinoma |
missense_variant |
6.1% (28/459) |
3 entries |
ENSG00000175054 |
ATR |
angiosarcoma |
sequence_alteration |
6.383% (3/47) |
1 entry |
ENSG00000175054 |
ATR |
Endometrial Endometrioid Adenocarcinoma |
frameshift_variant |
3.105% (39/1256) |
2 entries |
ENSG00000175054 |
ATR |
ovarian serous adenocarcinoma |
sequence_alteration |
3.863% (35/906) |
1 entry |
ENSG00000175054 |
ATR |
ovarian serous adenocarcinoma |
missense_variant |
3.863% (35/906) |
3 entries |
ENSG00000175054 |
ATR |
colon adenocarcinoma |
frameshift_variant |
3.793% (49/1292) |
4 entries |
ENSG00000175054 |
ATR |
esophageal squamous cell carcinoma |
missense_variant |
1.608% (11/684) |
3 entries |
ENSG00000175054 |
ATR |
melanoma |
sequence_alteration |
7.018% (12/171) |
2 entries |
ENSG00000175054 |
ATR |
bladder transitional cell carcinoma |
sequence_alteration |
6.1% (28/459) |
2 entries |
ENSG00000175054 |
ATR |
osteosarcoma |
sequence_alteration |
1.316% (2/152) |
2 entries |
ENSG00000175054 |
ATR |
lobular breast carcinoma |
missense_variant |
5.839% (16/274) |
3 entries |
ENSG00000175054 |
ATR |
Breast Carcinoma by Gene Expression Profile |
sequence_alteration |
3.182% (40/1257) |
1 entry |
ENSG00000175054 |
ATR |
Malignant Ovarian Mixed Epithelial Tumor |
sequence_alteration |
20.0% (2/10) |
1 entry |
ENSG00000175054 |
ATR |
colon adenocarcinoma |
missense_variant |
3.793% (49/1292) |
7 entries |
ENSG00000175054 |
ATR |
non-small cell lung carcinoma |
missense_variant |
4.167% (4/96) |
3 entries |
ENSG00000175054 |
ATR |
lung adenocarcinoma |
sequence_alteration |
2.823% (78/2763) |
3 entries |
ENSG00000175054 |
ATR |
prostate carcinoma |
sequence_alteration |
2.57% (11/428) |
1 entry |
ENSG00000175054 |
ATR |
pharyngeal squamous cell carcinoma |
missense_variant |
4.938% (4/81) |
1 entry |
ENSG00000175054 |
ATR |
rectal adenocarcinoma |
frameshift_variant |
2.364% (13/550) |
2 entries |
ENSG00000175054 |
ATR |
cecum adenocarcinoma |
stop_gained |
4.833% (13/269) |
2 entries |
ENSG00000175054 |
ATR |
papillary thyroid carcinoma |
frameshift_variant |
0.6135% (3/489) |
1 entry |
ENSG00000175054 |
ATR |
ovarian mucinous adenocarcinoma |
sequence_alteration |
7.407% (2/27) |
1 entry |
ENSG00000175054 |
ATR |
prostate carcinoma |
missense_variant |
2.57% (11/428) |
2 entries |
ENSG00000175054 |
ATR |
melanoma |
missense_variant |
7.018% (12/171) |
3 entries |
ENSG00000175054 |
ATR |
thyroid carcinoma |
missense_variant |
2.7% (25/926) |
1 entry |
ENSG00000175054 |
ATR |
Breast Carcinoma by Gene Expression Profile |
missense_variant |
3.182% (40/1257) |
2 entries |
ENSG00000175054 |
ATR |
lung adenocarcinoma |
frameshift_variant |
2.823% (78/2763) |
2 entries |
ENSG00000175054 |
ATR |
skin melanoma |
stop_gained |
4.655% (54/1160) |
1 entry |
ENSG00000175054 |
ATR |
clear cell renal carcinoma |
missense_variant |
0.7175% (11/1533) |
1 entry |
ENSG00000175054 |
ATR |
oral squamous cell carcinoma |
missense_variant |
1.901% (5/263) |
2 entries |
ENSG00000175054 |
ATR |
bile duct adenocarcinoma |
stop_gained |
2.08% (13/625) |
1 entry |
ENSG00000175054 |
ATR |
gastric adenocarcinoma |
frameshift_variant |
3.928% (37/942) |
2 entries |
ENSG00000175054 |
ATR |
hepatocellular carcinoma |
frameshift_variant |
2.742% (28/1021) |
2 entries |
ENSG00000175054 |
ATR |
Invasive Breast Carcinoma |
missense_variant |
16.33% (8/49) |
1 entry |
ENSG00000175054 |
ATR |
hepatocellular carcinoma |
missense_variant |
2.742% (28/1021) |
2 entries |
ENSG00000175054 |
ATR |
anaplastic oligodendroglioma |
missense_variant |
2.326% (2/86) |
2 entries |
ENSG00000175054 |
ATR |
head and neck squamous cell carcinoma |
missense_variant |
0.4525% (3/663) |
1 entry |
ENSG00000175054 |
ATR |
breast carcinoma |
frameshift_variant |
1.579% (26/1647) |
1 entry |
ENSG00000175054 |
ATR |
endometrial carcinoma |
missense_variant |
6.897% (2/29) |
2 entries |
ENSG00000175054 |
ATR |
HER2 Positive Breast Carcinoma |
stop_gained |
9.42% (13/138) |
1 entry |
ENSG00000175054 |
ATR |
lung adenocarcinoma |
stop_gained |
2.823% (78/2763) |
4 entries |
ENSG00000175054 |
ATR |
prostate adenocarcinoma |
frameshift_variant |
3.517% (76/2161) |
1 entry |
ENSG00000175054 |
ATR |
squamous cell lung carcinoma |
missense_variant |
3.94% (37/939) |
4 entries |
ENSG00000175054 |
ATR |
nasopharyngeal squamous cell carcinoma |
missense_variant |
1.19% (3/252) |
2 entries |
ENSG00000175054 |
ATR |
gastric adenocarcinoma |
missense_variant |
3.928% (37/942) |
3 entries |
ENSG00000175054 |
ATR |
salivary gland carcinoma |
stop_gained |
3.03% (1/33) |
1 entry |
ENSG00000175054 |
ATR |
Prostate Small Cell Carcinoma |
missense_variant |
5.263% (1/19) |
1 entry |
ENSG00000175054 |
ATR |
Intimal Sarcoma |
missense_variant |
12.5% (1/8) |
1 entry |
ENSG00000175054 |
ATR |
Merkel cell skin cancer |
stop_gained |
3.191% (3/94) |
1 entry |
ENSG00000175054 |
ATR |
breast phyllodes tumor |
missense_variant |
1.786% (1/56) |
1 entry |
ENSG00000175054 |
ATR |
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
missense_variant |
0.3788% (1/264) |
1 entry |
ENSG00000175054 |
ATR |
Duodenal Adenocarcinoma |
missense_variant |
5.882% (1/17) |
1 entry |
ENSG00000175054 |
ATR |
Tonsillar Squamous Cell Carcinoma |
missense_variant |
11.11% (1/9) |
1 entry |
ENSG00000175054 |
ATR |
ependymoma |
sequence_alteration |
1.852% (1/54) |
1 entry |
ENSG00000175054 |
ATR |
Merkel cell skin cancer |
sequence_alteration |
3.191% (3/94) |
1 entry |
ENSG00000175054 |
ATR |
squamous cell lung carcinoma |
stop_gained |
3.94% (37/939) |
1 entry |
ENSG00000175054 |
ATR |
angiosarcoma |
missense_variant |
6.383% (3/47) |
1 entry |
ENSG00000175054 |
ATR |
Adamantinomatous Craniopharyngioma |
missense_variant |
7.692% (1/13) |
1 entry |
ENSG00000175054 |
ATR |
esophageal adenocarcinoma |
stop_gained |
6.216% (34/547) |
1 entry |
ENSG00000175054 |
ATR |
Pancreatic Acinar Cell Carcinoma |
frameshift_variant |
2.941% (1/34) |
1 entry |
ENSG00000175054 |
ATR |
bile duct adenocarcinoma |
sequence_alteration |
2.08% (13/625) |
1 entry |
ENSG00000175054 |
ATR |
diffuse large B-cell lymphoma |
missense_variant |
0.5405% (2/370) |
1 entry |
ENSG00000175054 |
ATR |
pharyngeal squamous cell carcinoma |
frameshift_variant |
4.938% (4/81) |
1 entry |
ENSG00000175054 |
ATR |
papillary thyroid carcinoma |
missense_variant |
0.6135% (3/489) |
1 entry |
ENSG00000175054 |
ATR |
Endometrial Clear Cell Adenocarcinoma |
frameshift_variant |
7.407% (2/27) |
1 entry |
ENSG00000175054 |
ATR |
Gallbladder Adenocarcinoma |
conservative_inframe_deletion |
4.124% (8/194) |
1 entry |
ENSG00000175054 |
ATR |
anaplastic astrocytoma |
missense_variant |
1.449% (2/138) |
1 entry |
ENSG00000175054 |
ATR |
melanoma |
stop_gained |
7.018% (12/171) |
1 entry |
ENSG00000175054 |
ATR |
small intestinal adenocarcinoma |
stop_gained |
4.762% (1/21) |
1 entry |
ENSG00000175054 |
ATR |
ovarian clear cell adenocarcinoma |
sequence_alteration |
5.405% (2/37) |
1 entry |
ENSG00000175054 |
ATR |
Malignant Ovarian Mixed Epithelial Tumor |
stop_gained |
20.0% (2/10) |
1 entry |
ENSG00000175054 |
ATR |
anaplastic astrocytoma |
stop_gained |
1.449% (2/138) |
1 entry |
ENSG00000175054 |
ATR |
melanoma |
frameshift_variant |
7.018% (12/171) |
1 entry |
ENSG00000175054 |
ATR |
laryngeal squamous cell carcinoma |
missense_variant |
2.439% (1/41) |
1 entry |
ENSG00000175054 |
ATR |
Lung Sarcomatoid Carcinoma |
missense_variant |
7.143% (1/14) |
1 entry |
ENSG00000175054 |
ATR |
leiomyosarcoma |
missense_variant |
1.0% (1/100) |
1 entry |
ENSG00000175054 |
ATR |
multiple myeloma |
missense_variant |
0.2079% (1/481) |
1 entry |
ENSG00000175054 |
ATR |
pseudomyxoma peritonei |
missense_variant |
10.0% (1/10) |
1 entry |
ENSG00000175054 |
ATR |
marginal zone B-cell lymphoma |
missense_variant |
3.333% (1/30) |
1 entry |
ENSG00000175054 |
ATR |
Pleural Mesothelioma |
missense_variant |
0.7353% (1/136) |
1 entry |
ENSG00000175054 |
ATR |
basal cell carcinoma |
sequence_alteration |
11.76% (8/68) |
1 entry |
ENSG00000175054 |
ATR |
urothelial carcinoma |
sequence_alteration |
8.14% (7/86) |
1 entry |
ENSG00000175054 |
ATR |
Gastrointestinal stromal tumor |
frameshift_variant |
0.6757% (1/148) |
1 entry |
ENSG00000175054 |
ATR |
gastric tubular adenocarcinoma |
missense_variant |
50.0% (1/2) |
1 entry |
ENSG00000175054 |
ATR |
Endometrial Clear Cell Adenocarcinoma |
missense_variant |
7.407% (2/27) |
1 entry |
ENSG00000175054 |
ATR |
Thymic Undifferentiated Carcinoma |
missense_variant |
16.67% (1/6) |
1 entry |
ENSG00000175054 |
ATR |
small cell lung carcinoma |
sequence_alteration |
4.289% (19/443) |
1 entry |
ENSG00000175054 |
ATR |
bronchoalveolar adenocarcinoma |
missense_variant |
8.696% (2/23) |
1 entry |
ENSG00000175054 |
ATR |
bronchoalveolar adenocarcinoma |
sequence_alteration |
8.696% (2/23) |
1 entry |
ENSG00000175054 |
ATR |
ulcerative colitis |
missense_variant |
11.11% (1/9) |
1 entry |
ENSG00000175054 |
ATR |
small cell lung carcinoma |
frameshift_variant |
4.289% (19/443) |
1 entry |
ENSG00000175054 |
ATR |
neoplasm of mature B-cells |
missense_variant |
1.667% (1/60) |
1 entry |
ENSG00000175054 |
ATR |
esophageal adenocarcinoma |
frameshift_variant |
6.216% (34/547) |
1 entry |
ENSG00000175054 |
ATR |
salivary gland squamous cell carcinoma |
missense_variant |
50.0% (1/2) |
1 entry |
ENSG00000175054 |
ATR |
Pleural Epithelioid Mesothelioma |
missense_variant |
0.5025% (1/199) |
1 entry |
ENSG00000175054 |
ATR |
gastric adenocarcinoma |
conservative_inframe_deletion |
3.928% (37/942) |
1 entry |
ENSG00000175054 |
ATR |
pancreatic ductal adenocarcinoma |
stop_gained |
3.446% (58/1683) |
1 entry |
ENSG00000175054 |
ATR |
nasal cavity and paranasal sinus carcinoma |
sequence_alteration |
4.348% (1/23) |
1 entry |
ENSG00000175054 |
ATR |
neoplasm |
missense_variant |
6.897% (2/29) |
1 entry |
ENSG00000175054 |
ATR |
acute myeloid leukemia |
missense_variant |
1.76% (16/909) |
1 entry |
ENSG00000175054 |
ATR |
ovarian clear cell adenocarcinoma |
missense_variant |
5.405% (2/37) |
1 entry |
ENSG00000175054 |
ATR |
undifferentiated pleomorphic sarcoma |
missense_variant |
1.613% (1/62) |
1 entry |
ENSG00000175054 |
ATR |
Small Intestinal Diffuse Large B-Cell Lymphoma |
missense_variant |
50.0% (1/2) |
1 entry |
ENSG00000175054 |
ATR |
pharyngeal squamous cell carcinoma |
stop_gained |
4.938% (4/81) |
1 entry |
ENSG00000175054 |
ATR |
small cell lung carcinoma |
stop_gained |
4.289% (19/443) |
1 entry |
ENSG00000175054 |
ATR |
pharyngeal squamous cell carcinoma |
sequence_alteration |
4.938% (4/81) |
1 entry |